[go: up one dir, main page]

LV15600A - Curcumin dihydropyridone derivatives with anti-cancer activity - Google Patents

Curcumin dihydropyridone derivatives with anti-cancer activity

Info

Publication number
LV15600A
LV15600A LVP-20-41A LVP2020000041A LV15600A LV 15600 A LV15600 A LV 15600A LV P2020000041 A LVP2020000041 A LV P2020000041A LV 15600 A LV15600 A LV 15600A
Authority
LV
Latvia
Prior art keywords
derivatives
curcumin
dihydropyridone
cancer activity
cancer
Prior art date
Application number
LVP-20-41A
Other languages
Latvian (lv)
Inventor
Rufus ŠMITS
Original Assignee
Latvijas Organiskās Sintēzes Institūts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Latvijas Organiskās Sintēzes Institūts filed Critical Latvijas Organiskās Sintēzes Institūts
Priority to LVP-20-41A priority Critical patent/LV15600A/en
Priority to PCT/IB2021/052354 priority patent/WO2021234468A1/en
Priority to CA3177353A priority patent/CA3177353A1/en
Publication of LV15600A publication Critical patent/LV15600A/en
Priority to DKPA202270604A priority patent/DK181827B1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Šis izgudrojums ietver DHPDO kurkumīha atvasinājumus (6) ar doto vispārējo struktūru. Šiem DHPDO kurmumīna atvasinājumiem ir izteikta pretvēža aktivitāte, zemāka toksicitāte uz normālām šūnām. Specifiski šos savienojums var izmantot krūts vēža un kolorektālā vēža ārstēšanā.The present invention includes DHPDO curcumin derivatives (6) with the given general structure. These DHPDO mucinium derivatives have pronounced anti-cancer activity, lower toxicity to normal cells. Specifically, these compounds can be used in the treatment of breast cancer and colorectal cancer.

LVP-20-41A 2020-05-18 2020-05-18 Curcumin dihydropyridone derivatives with anti-cancer activity LV15600A (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
LVP-20-41A LV15600A (en) 2020-05-18 2020-05-18 Curcumin dihydropyridone derivatives with anti-cancer activity
PCT/IB2021/052354 WO2021234468A1 (en) 2020-05-18 2021-03-22 Curcumin dihydropyridone derivatives with anti-cancer activity
CA3177353A CA3177353A1 (en) 2020-05-18 2021-03-22 Curcumin dihydropyridone derivatives with anti-cancer activity
DKPA202270604A DK181827B1 (en) 2020-05-18 2022-12-13 CURCUMINDIHYDROPYRIDONE DERIVATIVES WITH ANTICANCER ACTIVITY

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
LVP-20-41A LV15600A (en) 2020-05-18 2020-05-18 Curcumin dihydropyridone derivatives with anti-cancer activity

Publications (1)

Publication Number Publication Date
LV15600A true LV15600A (en) 2021-11-20

Family

ID=75396831

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-20-41A LV15600A (en) 2020-05-18 2020-05-18 Curcumin dihydropyridone derivatives with anti-cancer activity

Country Status (4)

Country Link
CA (1) CA3177353A1 (en)
DK (1) DK181827B1 (en)
LV (1) LV15600A (en)
WO (1) WO2021234468A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3643308A1 (en) * 2017-06-23 2020-04-29 Cstone Pharmaceuticals Coumarin-like cyclic compound as mek inhibitor and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3643308A1 (en) * 2017-06-23 2020-04-29 Cstone Pharmaceuticals Coumarin-like cyclic compound as mek inhibitor and use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
OHYOSHI TAKAYUKI ET AL: "Concise total syntheses of phelligridins A, C, and D", RSC ADVANCES, vol. 9, no. 13, 1 January 2019 (2019-01-01), pages 7321 - 7323, XP055774100, Retrieved from the Internet <URL:https://pubs.rsc.org/en/content/articlepdf/2019/ra/c8ra10346a> DOI: 10.1039/C8RA10346A *

Also Published As

Publication number Publication date
WO2021234468A1 (en) 2021-11-25
DK202270604A9 (en) 2025-02-13
CA3177353A1 (en) 2021-11-25
DK181827B1 (en) 2025-02-12
DK202270604A1 (en) 2022-12-22

Similar Documents

Publication Publication Date Title
PH12019501116A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20
MX2025002382A (en) Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
ZA202300924B (en) Quinoxaline derivatives as anti-cancer drugs
EP4272731A3 (en) Compositions for the delivery of therapeutic agents and methods of use and making thereof
SA520420033B1 (en) Pharmaceutical compounds
MX2023001997A (en) Bicyclic compounds, compositions and use thereof.
NZ793445A (en) Cd73 inhibiting 2,4-dioxopyrimidine compounds
PH12021552395A1 (en) Compounds with anti-tumor activity against cancer cells bearing egfr or her2 exon 20 insertions
MX354256B (en) Derivatives of fluorene, anthracene, xanthene, dibenzosuberone and acridine and uses thereof.
MX2017004128A (en) Diaryl urea derivatives as p38 kinase inhibitors.
MY150136A (en) Picolinamide derivatives as kinase inhibitors
Huang et al. A multicentre randomised trial comparing weekly paclitaxel+ S-1 with weekly paclitaxel+ 5-fluorouracil for patients with advanced gastric cancer
JOP20190263A1 (en) RNAi factors to inhibit the expression of Alpha- EnaC and methods for their use
BR112015033053A2 (en) cancer treatment method in a subject, method of stimulating the immune system in a subject, method of increasing the distribution of an anticancer agent to a tumor cell, composition, and kit
NO20092339L (en) Universal tumor cell vaccine for anti-cancer therapeutic and prophylactic use
MX2018009408A (en) Rapaglutins, novel inhibitors of glut and use thereof.
MX2019009266A (en) PYRIDINES SUBSTITUTED WITH HYDROCARBYLSULFONIL AND ITS USE IN THE TREATMENT OF CANCER.
PH12020551495A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 19 mutations
LV15600A (en) Curcumin dihydropyridone derivatives with anti-cancer activity
PH12021552110A1 (en) Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions
EP4219458A3 (en) Novel barbituric acid derivatives, their preparation and use thereof as leukocyte transmigration inhibitors and for treating inflammatory diseases, autoimmune diseases and cancer
WO2012021609A3 (en) Neoadjuvant treatment of cancer with proleukin
PL426879A1 (en) Combination of isothiocyanates with organic selen compounds in drug carriers as a new pharmaceutical with antitumor activity
MX2022003997A (en) ANDROSTANE DERIVATIVES WITH ACTIVITY AS PURE OR PREDOMINANTLY PURE STIMULATORS OF SERCA2A FOR THE TREATMENT OF HEART FAILURE.
DE602005027739D1 (en) ARYLSUBSTITUTED BENZIMIDAZOLE AND IMIDAZOPYRIDINETHERS AS ACTIVE AGENTS AGAINST CANCER